Phase II study for indication expansion of TLX250-CDx doses
Filed with ASX · · 2 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Annual General Meeting - Presentation
- Annual General Meeting - Chairman and CEO Addresses
- ZIRCON Data Presented at AUA Confirms Efficacy in 2cm Masses
- Presentation to Accompany AI Development Program Update
- Telix Accelerates AI Development with Dedicaid Acquisition
Later from Telix Pharmaceuticals
- Lightpoint Acquisition to Expand Telix Urologic Pipeline
- Activities Report and Appendix 4C - June 2023 Quarter
- Q2 2023 Business Update to Accompany Quarterly Results
- First Patient Dosed in Phase 3 Illuccix China Study
- 1H 2023 Appendix 4D and Interim Report
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals